Skip to main content

Table 4 Differences in healthcare resource utilisation between different Interferon Beta formulations

From: Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)

 

Avonex®

Betaferon®

Extavia®

Plegridy®

Rebif®

Hospital admissions

3.24%

2.86%

5.80%

2.77%

2.96

OR

0.97

1.03

3.80

0.72

reference

95%CI

0.41, 2.25

0.37, 2.85

1.27, 11.85

0.16, 3.11

 

p-value

0.95

0.94

0.02

0.66

 

Emergency admissions

1.94%

2.3%

4.35%

2.54%

1.98%

OR

0.96

1.07

2.60

2.08

reference

95%CI

0.40, 2.27

0.43, 2.69

1.17, 4.17

1.08, 4.63

 

p-value

0.93

0.87

< 0.01

0.04

 

MS-related admissions

38.51%

53.74%

31.88%

37.06%

34.90%

OR

1.41

4.77

1.22

1.67

reference

95%CI

1.07, 2.04

2.74, 8.31

0.48, 3.15

1.12, 3.01

 

p-value

0.03

< 0.01

0.67

0.04

 
  1. Table shows percent of patients with hospital admissions, emergency admissions, and MS-related admissions for different Interferon Beta formulations (out of all individuals on treatment with each Interferon Beta formulation). OR, 95%CI, and p-values are reported from mixed effect logistic regression models adjusted by age, sex, and treatment duration (Rebif® was used as reference in the statistical models)